Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid

Vaccine

Volumn 26, Issue 47, 2008, Pages 5935-5943

  Tartz, Susanne ^a   Rüssmann, Holger ^b   Kamanova, Jana ^c   Sebo, Peter ^c   Sturm, Angelika ^a   Heussler, Volker ^a   Fleischer, Bernhard ^a,d   Jacobs, Thomas ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adenylate cyclase toxoid; Circumsporozoite protein; Plasmodium berghei; Salmonella; Type III secretion system; Vaccine

Indexed keywords

ADENYLATE CYCLASE TOXIN; CIRCUMSPOROZOITE PROTEIN; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT PROTEIN; SALMONELLOSIS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BORDETELLA; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOSOL; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INTERFERON PRODUCTION; LIVER CELL; MALARIA; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SALMONELLA; SPOROZOITE;

ADENYLATE CYCLASE TOXIN; ANIMALS; BACTERIAL PROTEINS; BORDETELLA; CD8-POSITIVE T-LYMPHOCYTES; IMMUNIZATION; IMMUNIZATION, SECONDARY; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM;

EID: 55249118572     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.057     Document Type: Article

References (50)

1. Nussenzweig R.S., Vanderberg J., Most H., and Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216 (1967) 160-162
2. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., and Nussenzweig V. Gamma interferon, CD8+T cells and antibodies required for immunity to malaria sporozoites. Nature 330 (1987) 664-666
3. Mueller A.K., Labaied M., Kappe S.H., and Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (2005) 164-167
4. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., and Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341 (1989) 323-326
5. Plebanski M., Gilbert S.C., Schneider J., Hannan C.M., Layton G., Blanchard T., et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 28 (1998) 4345-4355
6. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 (1998) 397-402
7. Sadoff J.C., Ballou W.R., Baron L.S., Majarian W.R., Brey R.N., Hockmeyer W.T., et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240 (1988) 336-338
8. Aggarwal A., Kumar S., Jaffe R., Hone D., Gross M., and Sadoff J. Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J Exp Med 172 (1990) 1083-1090
9. Flynn J.L., Weiss W.R., Norris K.A., Seifert H.S., Kumar S., and So M. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol 4 (1990) 2111-2118
10. Chinchilla M., Pasetti M.F., Medina-Moreno S., Wang J.Y., Gomez-Duarte O.G., Stout R., et al. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun 75 (2007) 3769-3779
11. Russmann H., Shams H., Poblete F., Fu Y., Galan J.E., and Donis R.O. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281 (1998) 565-568
12. Russmann H. Bacterial type III translocation: a unique mechanism for cytosolic display of heterologous antigens by attenuated Salmonella. Int J Med Microbiol 293 (2003) 107-112
13. Galan J.E. Salmonella interactions with host cells: type III secretion at work. Annu Rev Cell Dev Biol 17 (2001) 53-86
14. Russmann H., Igwe E.I., Sauer J., Hardt W.D., Bubert A., and Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 167 (2001) 357-365
15. Russmann H. Yersinia outer protein E, YopE. A versatile type III effector molecule for cytosolic targeting of heterologous antigens by attenuated Salmonella. Adv Exp Med Biol 529 (2003) 407-413
16. Panthel K., Meinel K.M., Sevil Domenech V.E., Trulzsch K., and Russmann H. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol 298 (2008) 99-103
17. Lotter H., Russmann H., Heesemann J., and Tannich E. Oral vaccination with recombinant Yersinia enterocolitica expressing hybrid type III proteins protects gerbils from amebic liver abscess. Infect Immun 72 (2004) 7318-7321
18. Schlecht G., Loucka J., Najar H., Sebo P., and Leclerc C. Antigen targeting to CD11b allows efficient presentation of CD4+and CD8+T cell epitopes and in vivo Th1-polarized T cell priming. J Immunol 173 (2004) 6089-6097
19. Osicka R., Osickova A., Basar T., Guermonprez P., Rojas M., Leclerc C., et al. Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites. Infect Immun 68 (2000) 247-256
20. Preville X., Ladant D., Timmerman B., and Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 65 (2005) 641-649
21. Mackova J., Stasikova J., Kutinova L., Masin J., Hainz P., Simsova M., et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 55 (2006) 39-46
22. Simsova M., Sebo P., and Leclerc C. The adenylate cyclase toxin from Bordetella pertussis-a novel promising vehicle for antigen delivery to dendritic cells. Int J Med Microbiol 293 (2004) 571-576
23. Tartz S., Kamanova J., Simsova M., Sebo P., Bolte S., Heussler V., et al. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria. Infect Immun 74 (2006) 2277-2285
24. Wang R.F., and Kushner S.R. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 100 (1991) 195-199
25. Obert S., O'Connor R.J., Schmid S., and Hearing P. The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex. Mol Cell Biol 14 (1994) 1333-1346
26. Russmann H., Weissmuller A., Geginat G., Igwe E.I., Roggenkamp A., Bubert A., et al. Yersinia enterocolitica-mediated translocation of defined fusion proteins to the cytosol of mammalian cells results in peptide-specific MHC class I-restricted antigen presentation. Eur J Immunol 30 (2000) 1375-1384
27. Kaniga K., Uralil J., Bliska J.B., and Galan J.E. A secreted protein tyrosine phosphatase with modular effector domains in the bacterial pathogen Salmonella typhimurium. Mol Microbiol 21 (1996) 633-641
28. Hoiseth S.K., and Stocker B.A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291 (1981) 238-239
29. Collazo C.M., and Galan J.E. The invasion-associated type-III protein secretion system in Salmonella--a review. Gene 192 (1997) 51-59
30. Franken K.L., Hiemstra H.S., van Meijgaarden K.E., Subronto Y., den Hartigh J., Ottenhoff T.H., et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif 18 (2000) 95-99
31. Jacobs T., Plate T., Gaworski I., and Fleischer B. CTLA-4-dependent mechanisms prevent T cell induced-liver pathology during the erythrocyte stage of Plasmodium berghei malaria. Eur J Immunol 34 (2004) 972-980
32. Sory M.P., Boland A., Lambermont I., and Cornelis G.R. Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Proc Natl Acad Sci U S A 92 (1995) 11998-12002
33. Kaniga K., Bossio J.C., and Galan J.E. The Salmonella typhimurium invasion genes invF and invG encode homologues of the AraC and PulD family of proteins. Mol Microbiol 13 (1994) 555-568
34. Domenech V.E., Panthel K., Meinel K.M., and Russmann H. Rapid clearance of a recombinant Salmonella vaccine carrier prevents enhanced antigen-specific CD8 T-cell responses after oral boost immunizations. Microbes Infect 7 (2005) 860-866
35. Hoffman S.L., Isenbarger D., Long G.W., Sedegah M., Szarfman A., Waters L., et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244 (1989) 1078-1081
36. Gilbert S.C., Schneider J., Hannan C.M., Hu J.T., Plebanski M., Sinden R., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20 (2002) 1039-1045
37. Anderson R.J., Hannan C.M., Gilbert S.C., Laidlaw S.M., Sheu E.G., Korten S., et al. Enhanced CD8+T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 172 (2004) 3094-3100
38. Bejon P., Kai O.K., Mwacharo J., Keating S., Lang T., Gilbert S.C., et al. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Eur J Immunol 36 (2006) 2264-2272
39. Dunachie S.J., Walther M., Vuola J.M., Webster D.P., Keating S.M., Berthoud T., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24 (2006) 2850-2859
40. Bejon P., Mwacharo J., Kai O., Mwangi T., Milligan P., Todryk S., et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 1 (2006) e29
41. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102 (2005) 4836-4841
42. Loucka J., Schlecht G., Vodolanova J., Leclerc C., and Sebo P. Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect Immun 70 (2002) 1002-1005
43. Fayolle C., Osickova A., Osicka R., Henry T., Rojas M.J., Saron M.F., et al. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J Virol 75 (2001) 7330-7338
44. El-Azami-El-Idrissi M., Bauche C., Loucka J., Osicka R., Sebo P., Ladant D., et al. Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18: role of toxin acylation and identification of the main integrin interaction domain. J Biol Chem 278 (2003) 38514-38521
45. Dadaglio G., Moukrim Z., Lo-Man R., Sheshko V., Sebo P., and Leclerc C. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect Immun 68 (2000) 3867-3872
46. Keating S.M., Bejon P., Berthoud T., Vuola J.M., Todryk S., Webster D.P., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 175 (2005) 5675-5680
47. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10 (2004) 406-410
48. Todryk S.M., Bejon P., Mwangi T., Plebanski M., Urban B., Marsh K., et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE 3 (2008) e2027
49. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38 (2008) 732-741
50. Korten S., Anderson R.J., Hannan C.M., Sheu E.G., Sinden R., Gadola S., et al. Invariant Valpha14 chain NKT cells promote Plasmodium berghei circumsporozoite protein-specific gamma interferon- and tumor necrosis factor alpha-producing CD8+T cells in the liver after poxvirus vaccination of mice. Infect Immun 73 (2005) 849-858